[1] De paulis T. The discovery of epidepride and its analogs as high affinity radioligands for imaging extrastriatal dopamine D2 receptors in human brain[J]. Curr Pharm Des, 2003, 9(8):673-696.
[2] Mukherjee J, Yang ZY, Brown T, et al. Preliminary assessment of extrastriatal dopamine D2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand,18F-fallypride[J]. Nucl Med Biol, 1999, 26:519-527.
[3] Christian BT, narayanan TK, Shi B, et al. Quantitation if striatal and extrastriatal D2 dopamine receptor using PET imaging of [18F]fallypride in nonhuman primates[J]. Synapse,2000, 38:71-79.
[4] Mukherjee J, Christian BT, Shi B, et al. Comparison of 18F-fallypride displacement in the thalamus by nicotine-induced and amphetamine-induced dopamine release[J]. J Nucl Med, 2002, 43:106P.
[5] Narendran R, Talbot PS, Slifstein M, et al. Effects of d-amphetamine on the binding of 18F-fallypride in striatal and extrastriatal regions in baboons:single bolus and bolus plus constant infusion studies[J]. J Nucl Med, 2002, 43:106P.
[6] Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers:Blood analysis,distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D2/D3 receptors[J]. Synapse, 2002,46:170-188.
[7] Kessler RM, Ansari SM, Li R, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs[J]. J Nucl Med, 2002, 43:15.
[8] Mukherjee J, Christian BT, Narayanan TK, et al. Evaluation of dopamine D2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride[J]. Neuropsychopharmacology, 2001, 25:476-488.